Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

Veracyte Inc

Healthcare US VCYT

48.69USD
0.89(1.86%)

Last update at 2026-06-03T20:00:00Z

Day Range

46.4949.40
LowHigh

52 Week Range

18.6130.52
LowHigh

Fundamentals

  • Previous Close 47.80
  • Market Cap1639.81M
  • Volume1451408
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA19.73M
  • Revenue TTM375.47M
  • Revenue Per Share TTM5.12
  • Gross Profit TTM 194.95M
  • Diluted EPS TTM-0.93

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -36.42700M -81.64900M -34.90900M -12.59900M -22.99900M
Minority interest - - - - -
Net income -36.56000M -75.56300M -35.84700M -16.48100M -22.99900M
Selling general administrative 76.52M 101.35M 36.73M 29.03M 23.96M
Selling and marketing expenses 97.56M 79.84M 52.39M 53.69M 41.31M
Gross profit 194.95M 145.11M 76.03M 83.84M 58.93M
Reconciled depreciation 25.93M 19.59M 7.94M 4.12M 3.92M
Ebit -41.08100M -81.90300M -35.38900M -15.12700M -21.03600M
Ebitda -15.15300M -62.31000M -26.73600M -7.80500M -17.11600M
Depreciation and amortization 25.93M 19.59M 8.65M 7.32M 3.92M
Non operating income net other 4.65M 0.25M 0.71M 3.21M 1.20M
Operating income -41.08100M -81.90300M -35.38900M -15.12700M -22.23300M
Other operating expenses 337.62M 301.42M 152.87M 135.50M 114.24M
Interest expense -4.65400M 0.24M 0.23M 0.68M 1.96M
Tax provision 0.13M -6.08600M - - -
Interest income 1.97M 0.14M - 0.68M 1.96M
Net interest income 1.77M -0.10600M -0.22900M -0.67700M -1.96300M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.13M -6.08600M 0.94M 3.88M 1.20M
Total revenue 296.54M 219.51M 117.48M 120.37M 92.01M
Total operating expenses 236.03M 227.02M 111.42M 98.97M 81.16M
Cost of revenue 101.58M 74.40M 41.45M 36.52M 33.08M
Total other income expense net 4.65M 0.25M 0.48M 2.53M 1.20M
Discontinued operations - - - - -
Net income from continuing ops -36.56000M -75.56300M -34.90900M -12.59900M -22.99900M
Net income applicable to common shares -36.56000M -75.56300M -34.90900M -12.59900M -22.99900M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 1137.82M 1156.42M 1187.83M 457.16M 275.21M
Intangible assets 88.59M 174.87M 202.73M 59.92M 65.02M
Earning assets - - - - -
Other current assets 7.96M 11.47M 17.22M 3.20M 2.23M
Total liab 93.72M 81.22M 91.31M 35.93M 35.76M
Total stockholder equity 1044.10M 1075.20M 1096.51M 421.23M 239.46M
Deferred long term liab - 4.53M 5.59M - -
Other current liab 41.19M 44.02M 42.39M 11.71M 13.73M
Common stock 0.07M 0.07M 0.07M 0.06M 0.05M
Capital stock 0.07M 0.07M 0.07M 0.06M 0.05M
Retained earnings -468.12100M -393.71700M -357.15700M -281.59400M -246.68500M
Other liab - 7.56M 13.06M 8.42M 6.09M
Good will 702.98M 695.89M 707.90M 2.73M 2.73M
Other assets 0.00000M 6.17M 2.95M 9.85M 2.04M
Cash 216.45M 154.25M 173.20M 349.36M 159.32M
Cash and equivalents - - - - -
Total current liabilities 61.24M 62.61M 64.15M 16.78M 17.47M
Current deferred revenue 2.01M 2.61M 4.65M 0.37M -
Net debt -203.82400M -139.52900M -154.34400M -337.04800M -145.71000M
Short term debt 5.11M 4.07M 4.76M 1.59M 1.41M
Short long term debt - - 1.13M - -
Short long term debt total 12.63M 14.72M 18.85M 12.32M 13.61M
Other stockholder equity 1536.17M 1500.19M 1468.68M 702.77M 486.09M
Property plant equipment - 30.86M 31.14M 8.99M 8.93M
Total current assets 285.62M 248.64M 243.10M 375.68M 187.69M
Long term investments - - - - -
Net tangible assets - 379.31M 185.88M 358.58M 171.71M
Short term investments 0.00000M 24.61M - - -
Net receivables 45.08M 44.02M 41.46M 18.46M 19.33M
Long term debt - - - 0.81M 0.69M
Inventory 16.13M 14.29M 11.22M 4.66M 6.81M
Accounts payable 12.94M 11.91M 12.36M 3.12M 2.33M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -24.01800M -31.34600M -15.08300M - -14.08000M
Additional paid in capital - - - - -
Common stock total equity - 0.07M 0.07M 0.06M 0.05M
Preferred stock total equity - - - - -
Retained earnings total equity - -393.71700M -357.15700M -281.59400M -246.68500M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 5.97M 6.17M 2.95M 2.00M 2.04M
Deferred long term asset charges - - - - -
Non current assets total 852.20M 907.79M 944.72M 81.48M 87.53M
Capital lease obligations 12.63M 14.72M 17.73M 11.51M 12.91M
Long term debt total - - - 0.81M 0.69M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -20.83800M 3.00M -1.00000M -42.73300M -1.87400M
Change to liabilities 0.15M 5.16M 0.71M -0.14100M -1.56800M
Total cashflows from investing activities -29.38700M -739.20600M -3.83700M -42.73300M -1.87400M
Net borrowings -1.28100M -1.28100M -0.10000M -25.20800M -0.29200M
Total cash from financing activities 3.49M 596.32M 203.59M 127.29M 59.50M
Change to operating activities -9.02700M 9.10M -3.20800M 4.86M -0.55300M
Net income -36.56000M -75.56300M -34.90900M -12.59900M -22.99900M
Change in cash -18.95000M -176.02100M 190.05M 81.32M 44.10M
Begin period cash flow 173.95M 349.97M 159.92M 78.60M 34.49M
End period cash flow 155.00M 173.95M 349.97M 159.92M 78.60M
Total cash from operating activities 7.54M -31.62100M -9.71100M -3.23200M -13.52100M
Issuance of capital stock 0.00000M 593.82M 193.83M 137.85M 55.04M
Depreciation 25.93M 19.59M 7.94M 4.12M 3.92M
Other cashflows from investing activities - -736.83000M - -39.97700M -
Dividends paid - - - - -
Change to inventory -3.01100M -1.46400M 1.06M -3.40400M 1.92M
Change to account receivables 1.10M -8.57100M 0.95M -6.16100M -0.45200M
Sale purchase of stock 7.94M 11.53M 207.54M 152.50M 59.39M
Other cashflows from financing activities -3.16700M 2.50M 9.86M 14.65M 4.75M
Change to netincome 27.62M 26.39M 15.55M 9.78M 5.87M
Capital expenditures 8.55M 5.38M 2.84M 2.76M 1.87M
Change receivables -4.49500M -8.57100M 0.95M -6.16100M -0.45200M
Cash flows other operating -2.09500M 4.69M -1.02800M -7.51000M -23.24000M
Exchange rate changes - - - - -
Cash and cash equivalents changes -18.35800M -174.50700M 190.05M 81.32M 44.10M
Change in working capital -16.38100M 4.22M -0.48100M -4.84600M -0.65100M
Stock based compensation 26.73M 22.52M 12.99M 9.81M 5.96M
Other non cash items 7.68M 3.87M 2.69M 0.31M 0.25M
Free cash flow -1.01400M -36.99700M -12.54800M -5.98800M -15.39500M

Peer Comparison

Sector: Healthcare Industry: Diagnostics & Research

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
VCYT
Veracyte Inc		 0.89 1.86% 48.69 - - 4.21 1.46 3.64 -26.6181
TMO
Thermo Fisher Scientific Inc		 -8.13 1.69% 473.95 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation		 1.97 1.12% 178.08 29.09 28.01 5.67 3.20 6.00 19.09
A
Agilent Technologies Inc		 2.35 1.74% 137.40 34.36 26.39 6.59 7.14 6.78 23.56
IDXX
IDEXX Laboratories Inc		 9.91 1.80% 560.73 49.99 45.66 11.29 27.85 11.46 34.46

Reports Covered

Stock Research & News

View All

Profile

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Veracyte Inc

6000 Shoreline Court, South San Francisco, CA, United States, 94080

Key Executives

Name Title Year Born
Ms. Bonnie H. Anderson Co-Founder & Exec. Chairwoman 1958
Mr. Marc A. Stapley CEO & Director 1970
Ms. Rebecca Chambers Exec. VP & CFO 1978
Dr. Giulia C. Kennedy Ph.D. Global Chief Scientific Officer & Chief Medical Officer 1959
Dr. Tina S. Nova Ph.D. Pres of CLIA U.S. Bus. 1954
Ms. Beverly Jane Alley CPA VP & Corp. Controller 1963
Mr. Jonathan Wygant VP & Chief Accounting Officer 1971
Mr. Steven French Sr. VP & Chief Information Officer NA
Ms. Annie McGuire Sr. VP & Gen. Counsel 1980
Ms. Tracy Morris VP of Global Corp. Communications NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.